Now That Brilinta's Approved, AZ Has to Sell It
Motley Fool
Regulatory "sword of Damocles" dangles over two big AZ drugs
Fierce Biotech
Brilinta
news tags
Abbott Laboratories
Amgen
Arena Pharmaceuticals
AstraZeneca
Bayer
Biogen Idec
biotech
Boston Scientific
Bristol-Myers Squibb
cancer
Celgene
China
Dendreon
diabetes
earnings
Eli Lilly
Europe
FDA
generics
Genzyme
GSK
hepatitis C
investors
JNJ
lawsuits
layoffs
M&A
Management
Medtronic
Merck
Novartis
obesity
patents
Pfizer
prostate cancer
Roche
Sanofi
Teva Pharmaceuticals
vaccines
Vivus